What is the prevalence of Ewings sarcoma?

TL;DR: Ewing sarcoma is a rare bone and soft tissue cancer with an estimated annual incidence of approximately 1 to 3 cases per million people in the United States and Europe. While it is considered a rare disease, it is the second most common primary bone malignancy in children and adolescents, typically occurring between the ages of 10 and 20.

How common is Ewing sarcoma?

Ewing sarcoma is classified as a rare disease. Because it primarily affects younger populations, the prevalence—the total number of people living with the condition at any given time—is lower than that of adult-onset cancers. According to the National Institutes of Health (NIH) Genetic and Rare Diseases Information Center (GARD), the incidence rate is relatively consistent across Western populations, with roughly 200 to 300 new cases diagnosed annually in the United States. Data from the DiseaseMaps.org community, which includes 242 members sharing their experience with Ewing sarcoma, provides a vital real-world perspective on the lived experience of these patients, reflecting the global reach of this rare diagnosis.

Who is most affected by Ewing sarcoma?

Epidemiological data indicates distinct patterns regarding age and gender for Ewing sarcoma:

• Age of onset: The peak incidence occurs during the second decade of life, with the majority of diagnoses made between ages 10 and 20. While rarer, it can also manifest in children under 5 and adults over 30.


• Gender distribution: Ewing sarcoma is slightly more common in males than in females, with a male-to-female ratio of approximately 1.5 to 1.


• Ethnic variation: There is a notable demographic disparity; Ewing sarcoma is significantly more common in individuals of European descent and is reported much less frequently in individuals of African or Asian descent.

What challenges exist in tracking Ewing sarcoma prevalence?

Accurate epidemiological tracking of Ewing sarcoma is complicated by several factors. While major cancer registries track new cases, the "true" prevalence can be difficult to ascertain due to the complexity of diagnosing rare sarcomas. Misdiagnosis can occur, especially in cases where the tumor arises in soft tissue (extraosseous Ewing sarcoma) rather than bone, as it may be confused with other small round blue cell tumors. Furthermore, because Ewing sarcoma requires specialized molecular testing to identify the characteristic EWSR1 gene translocations, underdiagnosis may occur in regions with limited access to advanced diagnostic pathology.

Is Ewing sarcoma considered an ultra-rare disease?

While Ewing sarcoma is rare, it is generally categorized as a "rare disease" rather than an "ultra-rare" condition because it is a well-recognized clinical entity within pediatric oncology. However, because it requires highly specialized, multidisciplinary care, it is often managed in centers of excellence. The rarity of the disease makes international collaboration and patient registries, such as those found on DiseaseMaps.org, essential for researchers to aggregate enough data to improve treatment protocols and outcomes for the Ewing sarcoma community.

Next steps

• Consult a specialist: Seek care at a high-volume sarcoma center, as specialized oncologists have the most experience with the unique clinical course of Ewing sarcoma.


• Connect with peers: Join the 242 members on DiseaseMaps.org to share experiences and find support from others navigating the challenges of a Ewing sarcoma diagnosis.


• Seek genetic counseling: Discuss the role of molecular testing and genetic screening with your clinical team to confirm the diagnosis and explore potential clinical trials.


• Review clinical trials: Visit ClinicalTrials.gov to search for ongoing research targeting specific molecular subtypes of Ewing sarcoma.

Medical disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• National Institutes of Health (NIH) Genetic and Rare Diseases Information Center (GARD): Ewing Sarcoma.


• Orphanet: Ewing Sarcoma (ORPHA: 790).


• National Cancer Institute (NCI): Ewing Sarcoma Treatment (PDQ®)–Patient Version.


• OMIM (Online Mendelian Inheritance in Man): Ewing Sarcoma (#612219).